Octreotide Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous Injection; IV Infusion
Available Strengths: SQ: (0.5 mg/mL, 1 mg/mL, 3 mg/mL), Infusion: 0.25 mg/mL
Reference Brands: Sandostatin® , Sandostatin®
Category:
Oncology Cancer Care
Octreotide (brand Sandostatin®) is used to treat carcinoid tumors, acromegaly, and GEP-NETs. Available in subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting formulations (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it controls tumor-related symptoms like diarrhea and flushing by inhibiting hormone release. Available through GMP-compliant suppliers in the US and EU for oncology treatment.
Octreotide is available in Subcutaneous Injection; IV Infusion
and strengths such as SQ: (0.5 mg/mL, 1 mg/mL, 3 mg/mL), Infusion: 0.25 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Octreotide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Octreotide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Octreotide, marketed under the brand name Sandostatin®, is a somatostatin analogue used in oncology to manage carcinoid tumors, acromegaly, and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Available as subcutaneous injections (0.5 mg/mL, 1 mg/mL, 3 mg/mL) and long-acting injections (Sandostatin LAR®) (10 mg, 20 mg, 30 mg), it works by inhibiting hormone secretion, controlling tumor-induced symptoms like diarrhea and flushing. Sourced from GMP-certified suppliers, Octreotide is widely available for global distribution in US and EU markets. It provides reliable therapeutic options for oncologists and healthcare providers treating complex neuroendocrine tumors.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing